Find Flumatinib Mesylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 895519-91-2, Flumatinib (mesylate), 95y8l63nbc, N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide methanesulfonate, 895519-91-2 (mesylate), Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-n-[6-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-3-pyridinyl]-3-(trifluoromethyl)-, monomethanesulfonate (9ci)
Molecular Formula
C30H33F3N8O4S
Molecular Weight
658.7  g/mol
InChI Key
ZSASDYCFROUKTJ-UHFFFAOYSA-N
FDA UNII
95Y8L63NBC

Flumatinib Mesylate
Flumatinib Mesylate is the orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.
1 2D Structure

Flumatinib Mesylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide
2.1.2 InChI
InChI=1S/C29H29F3N8O.CH4O3S/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40;1-5(2,3)4/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38);1H3,(H,2,3,4)
2.1.3 InChI Key
ZSASDYCFROUKTJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
95Y8L63NBC
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 895519-91-2

2. Flumatinib (mesylate)

3. 95y8l63nbc

4. N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Methanesulfonate

5. 895519-91-2 (mesylate)

6. Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-n-[6-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-3-pyridinyl]-3-(trifluoromethyl)-, Monomethanesulfonate (9ci)

7. Hhgv678 Mesylate

8. N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Mesylate

9. Unii-95y8l63nbc

10. Hh-gv-678 Mesylate

11. Schembl4889246

12. Chembl3901539

13. Dtxsid70237780

14. Bcp08647

15. Ex-a2059

16. Vkb51991

17. Flumatinib Mesylate [who-dd]

18. Mfcd28053502

19. Cs-1826

20. Da-33624

21. Hy-13905

22. Methanesulfonic Acid;4-[(4-methylpiperazin-1-yl)methyl]-n-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide

23. Ft-0752643

24. E73439

25. Q27271825

26. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(6-methyl-5-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-3-pyridinyl)-3-(trifluoromethyl)-, Methanesulfonate (1:1)

27. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(6-methyl-5-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-3-pyridinyl)-3-(trifluoromethyl)-, Monomethanesulfonate

2.4 Create Date
2010-10-11
3 Chemical and Physical Properties
Molecular Weight 658.7 g/mol
Molecular Formula C30H33F3N8O4S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count14
Rotatable Bond Count7
Exact Mass658.22975722 g/mol
Monoisotopic Mass658.22975722 g/mol
Topological Polar Surface Area162 Ų
Heavy Atom Count46
Formal Charge0
Complexity934
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 895519-91-2 / Flumatinib Mesylate API manufacturers, exporters & distributors?

Flumatinib Mesylate manufacturers, exporters & distributors 1

55

PharmaCompass offers a list of Flumatinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Flumatinib Mesylate manufacturer or Flumatinib Mesylate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Flumatinib Mesylate manufacturer or Flumatinib Mesylate supplier.

PharmaCompass also assists you with knowing the Flumatinib Mesylate API Price utilized in the formulation of products. Flumatinib Mesylate API Price is not always fixed or binding as the Flumatinib Mesylate Price is obtained through a variety of data sources. The Flumatinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Flumatinib Mesylate

Synonyms

895519-91-2, Flumatinib (mesylate), 95y8l63nbc, N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide methanesulfonate, 895519-91-2 (mesylate), Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-n-[6-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-3-pyridinyl]-3-(trifluoromethyl)-, monomethanesulfonate (9ci)

Cas Number

895519-91-2

Unique Ingredient Identifier (UNII)

95Y8L63NBC

About Flumatinib Mesylate

Flumatinib Mesylate is the orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.

Flumatinib Mesylate Manufacturers

A Flumatinib Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flumatinib Mesylate, including repackagers and relabelers. The FDA regulates Flumatinib Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flumatinib Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Flumatinib Mesylate Suppliers

A Flumatinib Mesylate supplier is an individual or a company that provides Flumatinib Mesylate active pharmaceutical ingredient (API) or Flumatinib Mesylate finished formulations upon request. The Flumatinib Mesylate suppliers may include Flumatinib Mesylate API manufacturers, exporters, distributors and traders.

Flumatinib Mesylate GMP

Flumatinib Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Flumatinib Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flumatinib Mesylate GMP manufacturer or Flumatinib Mesylate GMP API supplier for your needs.

Flumatinib Mesylate CoA

A Flumatinib Mesylate CoA (Certificate of Analysis) is a formal document that attests to Flumatinib Mesylate's compliance with Flumatinib Mesylate specifications and serves as a tool for batch-level quality control.

Flumatinib Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Flumatinib Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Flumatinib Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Flumatinib Mesylate EP), Flumatinib Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flumatinib Mesylate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty